Man in a yellow hat talking to a woman

Man in a yellow hat talking to a woman

This site is intended for U.S. Healthcare Providers

Discover Zepbound®

(tirzepatide) injection

true
Weight Reduction
Moderate-to-Severe OSA
Weight Reduction
Moderate-to-Severe OSA
backgroundOption
color
backgroundColor
neutral
textColor
auto
No more than $50/month
Starting July 1, millions of eligible Medicare Part D patients will pay no more than $50 per month* for Zepbound1,2
For eligible Medicare Part D patients with a Zepbound prescription. This information is not a guarantee of coverage. Actual eligibility will be determined by Medicare GLP-1 Bridge eligibility criteria. Visit https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-
1-bridge to learn more.

*Terms apply. Injection supplies sold separately.
backgroundOption
color
backgroundColor
background-delicate
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto

INDICATIONS

In combination with a reduced-calorie diet and increased physical activity, _Zepbound_ is indicated in:
Person Arm Spread
Adults with obesity, or with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity.3

Zepbound should not be used for cosmetic weight loss.
tile, title-fs-24px, description-fs-24px, ctatarget-sametab, ctaexitinterstitial-select
Moon Star
Adults with moderate-to-severe obstructive sleep apnea and obesity in combination with a reduced-calorie diet and increased physical activity.3
tile, title-fs-24px, description-fs-24px, ctatarget-sametab, ctaexitinterstitial-select

INDICATIONS

Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity:

  • to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
  • to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.

LIMITATIONS OF USE

Zepbound contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.

backgroundOption
color
backgroundColor
background-muted
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
additionalPadding
narrow
backgroundOption
color
backgroundColor
background-none
textColor
auto

GETTING PATIENTS STARTED

Getting Started with Zepbound
Access tips for the prior authorization submission process, view dosage guidance, order demo kits, and find other helpful resources.
Get patients started
backgroundOption
color
backgroundColor
background-none
textColor
auto
additionalPadding
narrow
backgroundOption
color
backgroundColor
neutral
textColor
auto
additionalPadding
slim
additionalMargin
none

COVERAGE AND SAVINGS

Coverage and Savings Support
Zepbound is available for patients with or without insurance.
Explore savings and coverage
backgroundOption
color
backgroundColor
neutral
textColor
auto
additionalPadding
none
additionalMargin
none
backgroundOption
color
backgroundColor
neutral
textColor
auto
additionalPadding
slim
additionalMargin
none
2.5 mg Zepbound (tirzepatide) pen, vial and KwikPen
ZEPBOUND 2.5 MG IS FOR TREATMENT INITIATION ONLY Zepbound® KwikPen® for single-patient-use

Explore formulary coverage in your area


Quickly check Zepbound coverage by NPI number and ZIP code.
Check coverage
backgroundOption
color
backgroundColor
neutral
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
additionalPadding
narrow
additionalMargin
none
backgroundOption
color
backgroundColor
background-muted
textColor
auto
additionalPadding
none
MECHANISM OF ACTION

How Zepbound Works

Dual-acting Zepbound works differently by activating GIP and GLP-1 receptors3
woman roller skating
woman roller skating

Show description

GIP and GLP-1 are naturally occurring hormones. Both GIP and GLP-1 receptors are found in areas of the brain involved in appetite regulation. GLP-1 regulates appetite and caloric intake. GIP may further regulate food intake when added to GLP-1 as suggested by nonclinical studies.

Zepbound works by reducing calorie intake and appetite, and reducing body weight with greater fat mass loss than lean mass loss.

In combination with a reduced-calorie diet and increased physical activity: Zepbound is for adults with obesity or with overweight in the presence of at least one weight-related comorbid condition, and for adults with moderate-to-severe OSA and obesity.3

Zepbound should not be used for cosmetic weight loss.
GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide-1; OSA=obstructive sleep apnea.
Shield warning icon

Select Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Zepbound and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Zepbound.

References
  1. USC Leonard D. Schaeffer Institute for Public Policy & Government Service. Available at: https://schaeffer.usc.edu/research/benefits-of-medicare-coverage-for-weight-loss-drugs/ [Accessed March 16, 2026].
  2. CMS. Available at: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge April 21, 2026 [Accessed April 22, 2026].
  3. Zepbound. Prescribing Information. Lilly USA, LLC.
backgroundOption
color
backgroundColor
background-muted
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
additionalPadding
narrow
Chats

Call Us

tile, ctaselection-link, ctatarget-sametab, ctaexitinterstitial-select
Dial 1-800-LillyRX
(1-800-545-5979) to contact Lilly Support Services
CMAT-22246 05/2026 © Lilly USA, LLC 2026. All rights reserved.
backgroundOption
color
backgroundColor
background-premium
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
additionalPadding
narrow
additionalMargin
none